The 20 children in the investigation had been diagnosed with ASD by PCPs who were trained using the ECHO (Extension for Community Healthcare Outcomes) Autism Screening Tool for Autism in Toddlers and Young Children (STAT).

Tocilizumab-bavi (Tofidence; Biogen) demonstrated a biosimilarity to tocilizumab (Actemra; Genentech) based on multifaceted clinical and non-clinical data for polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (sJIA) in children aged 2 years and up. This makes it the first tocilizumab biosimilar to be FDA-approved in the United States, according to Biogen.

A new study notes that coinfections, amongst other issues, can complicate diagnosis and management of respiratory infections in children.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.